Peripheral vascular disease treatment developer IDev has received the CE Mark for its nitinol stent in Europe.
The approval is for the design, development, and manufacture of devices for removal of inadvertently dislodged or misplaced objects from peripheral body vasculature, for palliative treatment of biliary strictures produced by malignant neoplasms, and for use in peripheral vasculature for failed percutaneous transluminal angioplasty (PTA), according to the Houston-based firm.
IDev is initially preparing a limited distribution strategy to elite interventional centers throughout Europe, said chairman and CEO Thomas Tully.
In other company news, IDev has hired a new executive management team. New officers include Eric Schlote as vice president, sales; Tony Anzalone as vice president, marketing; Tim Placek as vice president, regulatory; Gert Jansen as director, European sales; and John Dame as controller.
By AuntMinnie.com staff writers
May 4, 2006
Related Reading
IDev taps Tully, January 5, 2006
IDev Longhorn gets FDA nod, enters European market, May 18, 2005
Copyright © 2006 AuntMinnie.com
